Author

Dale E. Johnson

Unknown affiliation - Cited by 1,653

Biography

Dr. Dale E. Johnson is an Associate professor in the Department of Pharm, University of California, Berkeley and University of Michigan, located in USA. Dr. Dale E. Johnson is the author/editors/reviewer in several international journals. He published 10 articles in many journals and the articles are informative and got good citations.
Title
Cited by
Year
Interactions between traditional Chinese medicines and Western
E Chan, M Tan, J Xin, S Sudarsanam, DE JohnsonCurr Opin Drug Discov Devel 13 (1), 50-65, 2010201
252
2010
Functional consequences of mTOR inhibition
S Sudarsanam, DE JohnsonCurr Opin Drug Discov Devel 13 (1), 31-40, 2010201
147
2010
Plant folk medicines for gastrointestinal disorders among the main tribes of Sonora, Mexico
SF Moreno-Salazar, RE Robles-Zepeda, DE JohnsonFitoterapia 79 (2), 132-141, 2008200
65
2008
Evidence for a potential protective effect of carnitine-pantothenic acid co-treatment on valproic acid-induced hepatotoxicity
D Felker, A Lynn, S Wang, DE JohnsonExpert Review of Clinical Pharmacology 7 (2), 211-218, 2014201
47
2014
Human recombinant arginase enzyme reduces plasma arginine in mouse models of arginase deficiency
LC Burrage, Q Sun, SH Elsea, MM Jiang, SCS Nagamani, AE Frankel, ...Human molecular genetics 24 (22), 6417-6427, 2015201
45
2015
Screening for chemical contributions to breast cancer risk: a case study for chemical safety evaluation
MR Schwarzman, JM Ackerman, SH Dairkee, SE Fenton, D Johnson, ...Environmental health perspectives 123 (12), 1255-1264, 2015201
41
2015
Biotherapeutics: challenges and opportunities for predictive toxicology of monoclonal antibodies
DE JohnsonInternational journal of molecular sciences 19 (11), 3685, 2018201
33
2018
Clustering and its application in multi-target prediction
W Liu, DE JohnsonCurr Opin Drug Discov Devel 12 (1), 98-107, 2009200
25
2009
Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
V Ramakrishnan, D Powers, DE Johnson, U JeffryUS Patent 7,285,268, 2007200
23
2007
Current HIV therapeutics: mechanistic and chemical determinants of toxicity.
SK Chiao, DL Romero, DE JohnsonCurrent opinion in drug discovery & development 12 (1), 53-60, 2009200
23
2009
Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
V Ramakrishnan, D Powers, DE Johnson, U Jeffry, V BhaskarUS Patent 7,276,589, 2007200
22
2007
Biomarkers
H Larson, E Chan, S Sudarsanam, DE JohnsonComputational Toxicology: Volume II, 253-273, 2013201
12
2013
The ABCs of human alternative splicing: a review of ATP-binding cassette transporter splicing
S Srinivasan, JL Bingham, D JohnsonCurr Opin Drug Discov Devel 12, 149-58, 2009200
11
2009
Pharmacogenomics and adverse drug reactions; prospective screening for risk identification
DE Johnson, DA Smith, BK ParkCurrent opinion in drug discovery & development 12 (1), 27-30, 2009200
10
2009
Tools for green molecular design to reduce toxicological risk
D Faulkner, LKR Shen, Y Vanessa, DE Johnson, R Hemingway, ...Computational Systems Pharmacology and Toxicology, 36-5, 2017201
9
2017
Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
V Ramakrishnan, D Powers, DE Johnson, U JeffryUS Patent 8,017,116, 2011201
9
2011
Fusion of nonclinical and clinical data to predict human drug safety
DE JohnsonExpert Review of Clinical Pharmacology 6 (2), 185-15, 2013201
9
2013
Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
V Ramakrishnan, D Powers, DE Johnson, U Jeffry, V BhaskarUS Patent 7,87,148, 2011201
9
2011
Future of computational toxicology: Broad application into human disease and therapeutics
DE Johnson, AD Rodgers, S SudarsanamComputational Toxicology: Risk Assessment for Pharmaceutical and …, 2007200
9
2007
Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
V Ramakrishnan, D Powers, DE Johnson, U Jeffry, V BhaskarUS Patent 7,776,55, 2010201
8
2010